Recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating your assigned disorder in children and adolescents.
Explain the risk assessment you would use to inform your treatment decision making. What are the risks and benefits of the FDA-approved medicine? What are the risks and benefits of the off-label drug?
Explain whether clinical practice guidelines exist for this disorder and, if so, use them to justify your recommendations. If not, explain what information you would need to take into consideration.
Support your reasoning with at least three scholarly resources, one each on the FDA-approved drug, the off-label, and a non-medication intervention for the disorder. Attach the PDFs of your sources.
Resources:
Hilt, R. J., & Nussbaum, A. M. (2016). DSM-5 pocket guide for child and adolescent mental healthLinks to an external site.. American Psychiatric Association Publishing.
Chapter 14, “Psychosocial Interventions”
Chapter 15, “Psychotherapeutic Interventions”
Chapter 16, “Psychopharmacological Interventions”Links to an external site.
Thapar, A., Pine, D. S., Leckman, J. F., Scott, S., Snowling, M. J., & Taylor, E. A. (2015). Rutter’s child and adolescent psychiatry (6th ed.). Wiley Blackwell.
Chapter 43, “Pharmacological, Medically-Led and Related Treatments”
Walden University. (n.d.). Developing SMART goalsLinks to an external site.. https://academicguides.waldenu.edu/ld.php?content_id=51901492Links to an external site.
Zakhari, R. (2020). The psychiatric-mental health nurse practitioner certification review manual. Springer.
Chapter 5, “Psychopharmacology”
CriticalThinkRx. (2019, June 9). Module 5: Links to an external site.Specific drug classes: Focus on adverse effectsLinks to an external site. [Video]. YouTube. https://youtu.be/Gbq6RnOsGKQLinks to an external site.
CriticalThinkRx. (2019, June 9). Module 2: Use of psychotropics with youth_prevalence and concernsLinks to an external site. [Video]. YouTube. https://youtu.be/NRef-g4Ding